
The global Melnickneedles Syndrome market size was valued at USD 250.50 million in 2024 and is expected to reach USD 337.58 million by 2032, at a CAGR of 3.80% during the forecast period
The market growth is primarily driven by increasing awareness and advancements in genetic testing and molecular diagnostics, enabling earlier and more accurate identification of rare skeletal dysplasias such as Melnick Needles Syndrome
Moreover, the growing focus on precision medicine, improved access to specialized healthcare, and ongoing research into gene-based and symptomatic therapies are supporting market expansion by enhancing treatment outcomes and patient quality of life worldwide



